Learn More
R&D Systems™ CT-4
Description
CT-4 is a potent and selective histone deacetylase 8 (HDAC8) Degrader (PROTAC®) (DC50 = 1.8 nM after 24 h, Dmax 97%). Comprises a HDAC8-binding moiety joined by a linker to pomalidomide as the ligand for cereblon (CRBN) protein. Displays 20-fold selectivity over HDAC6 (DC50 = 38 nM after 24 h, Dmax 69%) and it does not degrade other HDACs. Displays significant effect on metastasis of MDA-MB-231 cells, and induces degradation and cell death in T-cell leukemia Jurkat cells. Outperformed HDAC8 inhibitors in oncology models. HDAC8 mediates signalling via scaffolding functions in HDAC8/p53/fusion protein complexes, also interacts with STAT3, cAMP and DEC1 via scaffolding functions.
PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license
Specifications
Specifications
| Chemical Name or Material | 3-((4-((8-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)carbamoyl)benzyl)oxy)-N-hydroxy-4-methoxybenzamide |
| CAS | 3057302-21-0 |
| Quantity | 5 mg |
| Product Line | Tocris |
| Target | Histone Deacetylase Degraders |
| Molecular Formula | C37H41N5O9 |
| Purity | 98% |
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.